Tag: genomics
-
AbbVie Licenses Engineered Crispr Cell Process
Drug maker AbbVie is acquiring a technology using the gene-editing process Crispr to produce new off-the-shelf engineered T-cells as disease therapies.
-
Engineered Cell Therapy Company Issues $588M IPO
A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO.
-
Cancer Immunotherapy Adapted for HIV
A biotechnology company is adapting and licensing its immunotherapy process, originally designed for cancer, as a cure for HIV infections.
-
Food Allergy Biotech Raises $40M in New Funds
A biotechnology company designing proteins in food products and therapies for people with food allergies is raising $40 million in its second venture round.
-
Crispr Heart Disease Biotech Raises $94M in New Funds
A company applying Crispr gene-editing technology to treat inherited heart disease is raising $94 million in its second venture funding round.
-
Biotech Licenses mRNA Technology for Aging
A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging.
-
Drug Maker Gains Access to Hidden Protein Immunotherapies
Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells.
-
Moderna Developing Flu, HIV, Nipah Vaccines
Moderna Inc., developer of a currently authorized Covid-19 vaccine, is expanding its vaccine pipeline to cover three more common infectious viral diseases.
-
Vaccine Shown Active Against New Covid-19 Variants
A current Covid-19 vaccine is shown in lab tests to produce antibodies that appear to protect against new mutations found in South Africa and the U.K.
-
CureVac, Bayer Partner on Covid-19 Vaccine Supply
Vaccine developer CureVac and global drug maker Bayer are partnering on further development, authorization, and supply of CureVac’s Covid-19 vaccine.